Merck, a leading science and technology company, today announced that Celonic AG, a Swiss contract development and manufacturing organization (CDMO), is upgrading its manufacturing facility with five of Merck’s Mobius(R) single-use bioreactors.
Celonic, which produces biosimilars and also offers a cell line development platform, will add 50-, 200- and 2,000-liter bioreactors to its development and manufacturing facility in Basel, Switzerland. The upgrade will expand Celonic’s upstream capabilities, improving flexibility and scalability.
